Xilio Therapeutics
NASDAQ: XLOWaltham, US · Founded 2020 · Delaware corporation · 96 employees on LinkedIn · 15 known investors
Find your way into Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
Founders & leadership
Xilio Therapeutics was founded in 2020 by René Russo.
RR
René RussoinFounder · President and Chief Executive Officer
JF
Joseph FarmerExecutive
TC
Timothy ClacksonExecutive
CF
Christopher FrankenfieldinChief Financial Officer and Chief Operating Officer
KL
Katarina LuptakovainChief Medical Officer2023–2026Katarina Luptakova is a hematologist and oncologist with approximately 20 years of experience in drug development across pharmaceutical and biotech companies, including work on investigational new drug applications, clinical trials, and product registration and launches. She serves as Chief Medical Officer of Xilio Therapeutics.
PC
Paul ClancyNamed on SEC filing
DC
Daniel CurranNamed on SEC filing
NH
RH
DL
Daniel LynchNamed on SEC filing
Board
PD
DG
Investors · 15
Bain Capital Life SciencesBostonvia Andrew Hack · board
Bay City CapitalSan Rafael · $5M – $10M
F-Prime CapitalCambridge · $3M – $10Mvia Robert Weisskoff · board
M VenturesLos Angeles · $10.8M
MRL Ventures FundCambridge · $25M
RA CapitalBoston
RiverVest Venture PartnersSt. Louis · $500K – $3M
Solasta VenturesBoston
SV Health InvestorsBoston · $1M – $20M
Atlas VenturereportedCambridge · $500K – $1Mvia David Grayzel · board
Bain Capitalreported
Deerfield Management CompanyreportedNew York
Rock Springs CapitalreportedBaltimore
SV7 Impact MedicinereportedLondon
Takeda VenturesreportedCambridge · $1M – $5M
Reported raises · per SEC filings
Form D private placements$145.2M disclosed across 2 of 5 rounds · 1900–2026
▶$95MraisedFeb 2021 · 17 investors · BiotechnologyRule 506(b)
▶$95MraisedFeb 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rachel HumphreyDirector
- Andrew HackDirector
- David GrayzelDirector
- Daniel LynchDirector
- Michael RossDirector
- Joseph FarmerExecutive Officer
- Rene RussoExecutive Officer, Director
- Timothy ClacksonExecutive Officer
- Paul ClancyDirector
- Daniel CurranDirector
- David GardnerDirector
- Offering amount
- $95M
- Amount sold
- $95M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$50.2MraisedJan 2021 · 16 investors · BiotechnologyRule 506(b)
▶$50.2MraisedJan 2021 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul ClancyDirector
- Daniel CurranDirector
- Peter DudekDirector
- David GrayzelDirector
- Nancy HongDirector
- Rachel HumphreyDirector
- Daniel LynchDirector
- Michael RossDirector
- Robert WeisskoffDirector
- Joseph FarmerExecutive Officer
- Rene RussoExecutive Officer, Director
- Timothy ClacksonExecutive Officer
- Offering amount
- $50.2M
- Amount sold
- $50.2M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Xilio Therapeutics went on to found or lead other companies.
Competitors · 5
by search overlap
Exelixis39 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Eli Lilly37 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Elicio37 shared keywordsElicio Therapeutics is a biopharmaceutical company focused on developing therapeutic treatments.
Solu34 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Bioworld29 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Xilio Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Xilio Therapeutics do?
- Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
- Who founded Xilio Therapeutics?
- Xilio Therapeutics was founded by René Russo in 2020.
- Who are Xilio Therapeutics's investors?
- Xilio Therapeutics's investors include Bain Capital Life Sciences, Bay City Capital, F-Prime Capital, M Ventures, MRL Ventures Fund, RA Capital, RiverVest Venture Partners, Solasta Ventures and 7 more.
- How much funding has Xilio Therapeutics raised?
- Xilio Therapeutics has disclosed $145.2M raised across 2 of its 5 known rounds.
- Where is Xilio Therapeutics headquartered?
- Xilio Therapeutics is headquartered in Waltham, US.